臺灣博碩士論文加值系統

Aim:
The main purpose of this study is to explore the natural history of peripheral arterialdisease (PAD) in type 2 diabetes, including prevalence, incidence, mortality, risk
factors and potential regression.
Study design and methods:
A clinic for screening diabetic complications has been set up since July 1996. Till Dec 2002, 3,632 type 2 diabetic patients were referred for a baseline screening. Among
them, there were 1,577 subjects were followed with a baseline ABI>0.9 and were analyzed for incidence of PAD. Among the patients for incidence study, there were 344
cases over 60 years old with adiponectin data. The effect of adiponectin level on PAD incidence was further analyzed. Age, sex, duration of diabetes, hemoglobin A1c,
systolic/diastolic blood pressure, triglyceride, total cholesterol, smoking, exercise, body mass index, college education were also obtained and analyzed with Students t-test, Chi-square (or Fisher’s exact test), and correlations. Logistic regression, Cox regression.and Monte Carlo Markov Chain method were used for the analyses of the risk factors of prevalence and incidence, and progression and/or regression for the natural history of PAD among type 2 diabetes. P below 0.05 was considered statistic significance.
Results:
The prevalence of PAD was 5.95 % in a group of type 2 diabetes with a mean duration of 9.02 ± 8.00 years. The incidence was estimated at 1.14 % per year during 4.24 ± 2.08 years of follow-up. ABI > 1.4 or ABI < 0.9 were ndependent risk factors for all-cause and cardiovascular mortality in subjects with type 2 diabetes. Old age,
smoking, poor glycemic or blood pressure control, dyslipidemia were significant risk factors for PAD prevalence, incidence, and mortality (for ABI between 0.9 and 1.4). Hypoadiponectinemia (<3.75 μg/ml) was associated with new PAD onset for those aged over 60. Incident cases, mild PAD (ABI 0.7~0.9 vs. < 0.7), and better blood
pressure control, higher education level, and higher BMI were salutary factors for regression of PAD.
Conclusion:
Ankle-brachial index (ABI) is still a good, if not the best, screening tool for peripheral arterial disease in type 2 diabetic patients. Abnormal ABI, either below 0.9 or above 1.4, is associated with a significantly higher all-cause or cardiovascular mortality in patients
with type 2 diabetes. Age is the strongest factor for abnormal ABI and mortality. Among the modifiable risk factors, glycemic, lipid and blood pressure control are
important to prevent new PAD. Moreover, once a low ABI is detected, aggressive treatment should be instituted because one third or more patients might have a chance
to return normal ABI before they progress to a severer degree of PAD with ABI<0.7.

摘要 3
壹、研究緣起 5
貳、文獻探討
一、 周邊動脈疾病之流行病學 7
二、 周邊動脈疾病發生率之危險因子 8
三、 脂締素與周邊動脈疾病 9
參、研究目的 11
肆、研究方法
一、研究架構 12
二、周邊動脈疾病之流行病學 13
三、周邊動脈疾病發生率之危險因子 14
四、脂締素與周邊動脈疾病 14
伍、研究結果 15
六、討論 23
七、參考文獻 31
Appendix 43

1. Criqui MH, Fronek A, Barret-Connor E, Klauber MR, Gabriel S. The prevalence of peripheral arterial disease in a defined population. Circulation 71: 510- 515, 1985
2. Ogren M, Hedblad B, Isacsson SO, Janzon L, Jungquist G, Lindell SE. Ten year cerebrovascular morbidity and mortality in 68 year old men with asymptomatic
carotid stenosis. BMJ 310: 1294-8, 1995
3. Leng GC, Fowkes FGR, Lee AJ, Dunbar J, Housley E, Ruckley CV. Use of ankle brachial pressure index to predict cardiovascular events and death: a cohort study.
BMJ 313:1440-1444, 1996
4. Vogt MT, Cauley JA, Newman AB, Kuller LH, Hulley SB. Decreased ankle/arm blood pressure index and mortality in elderly women. JAMA 270: 465-469, 1993
5. Beach KW, Bedford GR, Bergelin RO, Martin DC, Vandenberghe N, Zaccardi M, Strandness DE Jr. Progression of lower-extremity arterial occlusive disease in type
2 diabetes mellitus. Diabetes Care 11: 464-472, 1998
6. Katsilambros NL, Tsapogas PC, Arvanitis MP, Tritos NA, Alexiou ZP, Rigas KL: Risk factors for lower-extremity arterial disease in non-insulin-dependent diabetic
persons. Diabet Med 13: 243-246, 1996
7. Beks PJ, MacKaay AJ, de Neeling JN, et al. Peripheral arterial disease in relation to glycemic level in an elderly Caucasian population: the Hoorn study.
Dibetologia 38: 86-96, 1995
8. Premalatha G, Shanthirani S, Deepa R, Markovitz J, Mohan V. Prevalence and risk factors of peripheral vascular disease in a selected south India population. Diab
Care 23: 1295-1300, 2000
9. Reunanen A, Takkenen H, Aroma A: Prevalence of intermittent claudication and its effect on mortality. Acta Med Scand 211: 249-256, 1982
10. Jelnes R, Gaardsting O, Hougaard-Jensen K, Baekgaard N, Tonnesen KH, Schroeder T: Fate in intermittent claudication: Outcome and risk factors. Br Med J
293: 1137-1140, 1986
11. Criqui MH, Coughlin SS, Fronek A: Non-invasive diagnosed peripheral arterial disease as a predictor of mortality: Results from a prospective population-based
study. Circulation 72: 768-773, 1985
12. Howell MA, Colgan MP, Seeger RW, Ramsey DE, Sumner DS. Relationship of severity of lower limb peripheral vascular disease to mortality and morbidity: A six-year follow-up study. J Vasc Surg 9: 691-7, 1989
13. Vogt MT, McKenna M, Anderson SJ, Wolfson SK, Kuller LH. The relationship between ankle-arm index and mortality in older men and women. J Am Geriatr Soc 41: 523-530, 1993
14. Kornitzer M, Dramaix M, Sobolski J, Degre S, De Backer G. Ankle/arm pressure index in asymptomatic middle-aged males: An independent predictor of ten-year coronary heart disease mortality. Angiology 46: 211-219, 1996
15. Criqui MH, Langer RD, Fronek A, Feigelson HS, Klauber MR, McCann TJ, Browner D. Mortality over a period of 10 years in patients with peripheral arterial disease. N Engl J Med 326: 381-6, 1992
16. Laakso M. Glycemic control and the risk for coronary heart disease in patients with non-insulin dependent diabetes mellitus. The Finnish Studies. Ann Intern
Med 124: 127-130, 1996
17. Wei M, Gaskill SP, Haffner SM, Stern MP. Effects of diabetes and level of glycemia on all-cause and cardiovascular mortality. Diabetes Care 21: 1167-1173,
1998
18. Rose GA: The diagnosis of ischemic heart pain and intermittent claudication in field survey. Bull WHO 27: 645-658, 1962
19. Criqui MH, Fronek A, Klauber MR, Barret-Connor E, Gabriel S: The sensitivity, specificity, and predictive value of traditional clinical evaluation of peripheral
artery disease: Results from a non-invasive testing in a defined population. Circulation 71: 516-521, 1985
20. Boyko EJ, Ahroni JH, Davignon D, Stensel V, Prigeon RL, Smith DG. Diagnostic utility of the history and physical examination for peripheral vascular disease
among patients with diabetes mellitus. J Clin Epidemiol 50: 659-668, 1997
21. American Diabetes Association. Peripheral arterial disease in people with diabetes:Diab Care 26: 3333-41, 2003
22. Adler AI, Steven RJ, Neil A, Strtton IM, Boulton AJ, Holman RR. UKPDS 59: Hyperglycemia and other potentially modifiable risk factors for peripheral vascular disease in type 2 diabetes. Diab Care 25: 894-899, 2002
23. Brand FN, Abbott RD, Kannel WB. Diabetes, intermittent claudication and risk of cardiovascular events. The Framingham Study. Diabetes 38:504–9, 1989
24. Dormandy J, Heeck L, Vig S. Predicting which patients will develop chronic critical leg ischemia. Semin Vasc Surg 12:138– 41, 1999
25. Criqui MH, Browner D, Fronek A, Klauber MR, Caughlin SS, Barrett-Connor E, Gabriel S. Peripheral arterial disease in large vessels is epidemiologically distinct
from small vessel disease: an analysis of risk factors. Am J Epidemiol 129:1110–9, 1989
26. Price JF, Lee AJ, Fowkes FG. Hyperinsulinemia: a risk factor for peripheral arterial disease in a non diabetic general population. J Cardiovasc Risk 3:501– 5, 1996
27. Kannel WB, Shurleff D. The Framingham Study. Cigarettes and the development of intermittent claudication. Geriatrics 28:61 –8, 1973
28. Murabito JM, D’Agostino RB, Silbershatz H, Wilson PWF. Intermittent claudication: a risk profile from the Framingham heart study. Circulation 96:44– 9,1997
29. Fowkes FG, Housley E, Riemersma RA, Macintyre CC, Cawood EH, Ruckley CV. Smoking, lipids, glucose intolerance and blood pressure as risk factor for
peripheral atherosclerosis compared with ischemic heart disease in the Edinburgh Artery Study. Am J Epidemiol 135:331– 340, 1992
30. Ingolfsson IO, Sigurdsson G, Sigraldoson H, Thorgeirsson G, Sigfusson N. A marked decline in the prevalence and incidence of intermitten claudication in
leelandic men 1968– 1986: a strong relationship to smoking and serum cholesterol. The Reykjavik Study. J Clin Epidemiol 47:1237– 43, 1994
31. Jonason T, Bergstrom R. Cessation of smoking in patients with intermittent claudication: effects on the risk of peripheral vascular complications, myocardial
infarction and mortality. Acta Med Scand 221: 253– 60, 1987
32. Celermajer DS, Sorensen KE, Georgakopoulos D, Bull C, Thomas O, Robinson J, Deanfield JE. Cigarette smoking and associated with dose-related and potentially reversible impairment of endothelium dependent dilation in healthy young adults. Circulation 88:2149– 55, 1993
33. Kannel WB. The demographics of claudication and the aging of the American population. Vasc Med 1:60– 4, 1996
34. Hooi JD, Kestes AD, Stoffers HE, Overdijk MM, Von Rec JW, Knottners JA. Incidence of and risk factors for asymptomatic peripheral arterial occlusive disease: a longitudinal study. Am J Epidemiol 153:666– 72, 2001
35. Kannel WB, Skinner JJ, Schwartz MJ, Shurtleff D. Intermittent claudication:incidence in the Framingham study. Circulation 41:875– 83, 1970
36. Zimmerman BR, Palumbo PJ, Fallon WM, Ellefson RD, Osmundson PJ, Kazmier FJ. A prospective study of peripheral occlusive arterial disease in diabetes: III.
Initial lipid and lipoprotein findings. Mayo Clinic Proc 56:233– 42, 1981
37. Boushey CJ, Beresford SA, Omenn GS, Motulsky AG. A quantitative assessment of plasma homocysteine as a risk factor for vascular disease: probable benefits of
increasing folic acid intake. JAMA, J Am Med Assoc 274:1049– 57, 1995
38. Smith FB, Lowe GD, Lee AJ, Romley A, Leng GC, Fowkes FG. Smoking, hemoreologic factors, and progression of peripheral arterial disease in patients with claudication. J Vasc Surg 28:129– 35, 1998
39. Philipp CS, Cisar LA, Kim HC, Wilson AC, Saidi P, Kostis JB. Association of hemostatic factors with peripheral vascular disease. Am Heart J 134:978– 84,
1997
40. Arita Y, Kihara S, Ouchi N, Takahashi M, Maeda K, Miyagawa J, Hotta K, Shimomura I, Nakamura T, Miyaoka K, Kuriyama H, Nishida M, Yamashita S,Okubo K, Matsubara K, Muraguchi M, Ohmoto Y, Funahashi T, Matsuzawa Y.
Paradoxical decrease of an adipose-specific protein, adiponectin, in obesity. Biochem Biophys Res Commun 257: 79-83, 1999
41. Hotta K, Funahashi T, Arita Y, Takahashi M, Matsuda M, Okamoto Y, Iwahashi H, Kuriyama H, Ouchi N, Maeda K, Nishida M, Kihara S, Sakai N, Nakajima T,Hasegawa K, Muraguchi M, Ohmoto Y, Nakamura T, Yamashita S, Hanafusa T,
Matsuzawa Y. Plasma concentrations of a novel adipose-specific protein,adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20:1595-1599, 2000
42. Yang YS, Lee WJ, Funahashi T, Tanaka S, Matsuzawa Y, Chao CL, Chen CL, Tai TY, Chuang LM. Plasma adiponectin levels in overweight and obese Asians. Obes Res 10: 1104-1110, 2002
43. Huang KC, Chen CL, Chuang LM, Ho SR, Tai TY, Yang YS. Plasma adiponectin levels and blood pressures in nondiabetic adolescent females. J Clin Endocrinol
Metab 88: 4130-4134, 2003
44. Shurk T, Van Harmelen V, Lee YM, Wirth A, Hauner H. Relationship between IL-6, Leptin and Adiponectin and Variables of Fibrinolysis in Overweight and Obese Hypertensive Patients. Horm Metab Res 34: 659-663, 2002
45. Engeli S, Feldpausch M, Gorzelnaik K, Hartwig F, Heintze U, Janke J, Mohlig M,Pfeiffer AF, Luft FC, Sharma AM. Association between adiponectin and mediators
of inflammation in obese women. Diabetes 52: 942-947, 2003
46. Fernandez-Real JM, Lopez-Bermejo A, Casamitjana R, Ricart W. Novel interactions of adiponectin with the endocrine system and inflammatory parameters. J Clin Endocrinol Metab 88: 2714-2718, 2003
47. Krakoff J, Funahashi T, Stehouwer CD, Schalkwijk CG, Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay RS. Inflammatory markers, adiponectin, and risk of type 2 diabetes in Pima Indian. Diabetes Care 26:1745-1751, 2003
48. Matsubara M, Namioka K, Katayose S. Decreased plasma adiponectin concentrations in women with low-grade C-reactive protein elevation. Eur J Endocrinol 148: 657-662, 2003
49. Kishida K, Nishizawa H, Maeda N, Kobayashi H, Hiraoka H, Matsuzawa Y. Reciprocal association of C-reactive protein with adiponectin in blood stream and
adipose tissue. Circulation 107: 671-674, 2003
50. Shimabukuro M, Higa N, Asahi T, Oshiro Y, Takasu N, Tagawa T, Ueda S, Shimomura I, Funahashi T, Matsuzawa Y. Hypoadiponectinemia is closely linked to endothelial dysfunction in man. J Clin Endicrinol Metab 88: 3236-3240, 2003
51. Kumada M, Kihara S, Sumitsuji S, Kawamoto T, Matsumoto S, Ouchi N, Arita Y, Okamoto Y, Shimomura I, Hiraoka H, Nakamura T, Matsuzawa Y. Arterioscler Thromb Vasc Biol 23: 85-89, 2003
52. Ouchi N, Kihara S, Arita Y, Maeda K, Kuriyama H, Okamato Y, Hotta K, Nishida M, Takahashi M, Nakamura T, Yamashita S, Funahashi T, Matsuzawa Y. Novel
modulator for endothelial adhesion molecules: adipocyte- derived plasma protein adiponectin. Circulation 100: 2473-2476, 1999
53. Maeda N, Shimomura I, Kishida K, Nishizawa H, Matsuda M, Nagaretani J, Furuyama N, Kondo H, Takahashi M, Arita Y, Komuro R, Ouchi N, Kihara S, Tochino Y, Okutomi K, Horie M, Takeda S, Aoyama T, Funahashi T, Matsuzawa Y.
Diet-induced insulin resistance in mice lacking adiponectin/ACRP30. Nat Med 8; 731-737, 2002
54. Yokota T, Oritani K, Takahashi I, Ishikawa J, Matsuyama A, Ouchi N, Kihara S, Funahashi T, Tenner AJ, Tomiyama Y, Matsuzawa Y. Adiponectin, a new member
of the family of soluble defense collagens, negatively regulates the growth of myelomonocytic progenitors and the functions of macrophages. Blood 96:1723-1732, 2000
55. Ouchi N, Kihara S, Arita Y, Nishida M, Matsuyama A, Okamoto Y, Ishigami M, Kuriyama H, Kishida K, Nishizawa H, Hotta K, Muraguchi M, Ohmoto Y, Yamashita S, Funahashi T, Matsuzawa Y. Adipocyte-derived plasma protein,
adiponectin, suppresses lipid accumulation and class A scavenger receptor expression in human monocyte-derived macrophages. Circulation 103: 1057-1063,2001
56. Chen H, Montagnani M, Funahashi T, Shimomura I, Quon MJ. Adiponectin stimulates production of nitric oxide in vascular endothelial cells. J Biol Chem 27:27, 2003
57. Klein R, Klein BE, Moss SE, Davis MD. Demets DL. The Wisconsin epidemiology study of diabetic retinopathy III. Prevalence and risk of diabetic retinopathy when age at diagnosis is 30 or more years. Arch Ophthalmology
102:527-32, 1984
58. American Diabetes Association. Eye care guidelines for patients with diabetes mellitus. Diab Care 11:745-746, 1988
59. DeFronzo RA. Diabetic nephropathy: etiological and therapeutic consideration. Diabetes Rev 3:510-514, 1995
60. Mogensen CE, Keane WF, Bennett PH, Jerums G, Parving H-H, Passa P, Steffes MW, Striker GE, Viberti GC: Prevention of diabetic renal disease with special reference to microalbuminuria. Lancet 346:1080-1084, 1995
61. American Diabetes Association. Diabetic Nephropathy. Diab Care 20: suppl1:s24-s27, 1997
62. American Diabetes Association. Diabetic neuropathies. Diab Care 28: 956-962,2005
63. Jiang YD, Chuang LM, Wu HP, Tai TY, Lin BJ. Role of an outpatient clinic in screening chronic complications of diabetes: a model for diabetes managed care. J Formos Med Assoc. 97: 521-7, 1998
64. Anonymous. Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 352(9131):854-65, 1998
65. Jiang YD, Yen CJ, Chou WL, Kuo SS, Lee KC, Chiu KC, Chunag LM. Interaction of the G182C polymorphism in the APOA5 gene and fasting plasma glucose on plasma triglycerides in Type 2 diabetic subjects. Diabet Med 2005 (in press)
66. Tseng CH. Prevalence and risk factors of peripheral arterial obstructive disease in Taiwanese type 2 diabetic patients. Angiology 54:331-8, 2003
67. Wattanakit K, Folsom AR, Selvin E, Weatherley BD, Pankow JS, Brancati FL, Hirsch AT Risk factors for peripheral arterial disease incidence in persons with
diabetes: the Atherosclerosis Risk in Communities (ARIC) Study. Atherosclerosis 180: 389-397, 2005
68. Edmonds ME, Morrison N, Laws JW, Watkins PJ. Medial arterial calcification and diabetic neuropathy. Br Med J 284:928-930, 1982
69. Young MJ, Adams JE, Anderson GF, Boulton AJ, Cavanagh PR. Medial arterial calcification in the feet of diabetic patients and matched non-diabetic control
subjects. Diabetologia 36:615-621, 1993
70. Orchard TJ, Strandess DE Jr, Assessment of peripheral vascular disease in diabetes: report and recommendations of an international workshop sponsored by American Diabetes Association and American Heart Association. 18-20 Sep 1992,
New Orleans, Louisiana. Circulation 88:819-828, 1993
71. Resnick HE, Lindsay RS, McDermott MM, Devereux RB, Jones KL, Fabsitz RR, Howard BV. Relationship of High and Low Ankle Brachial Index to All-Cause and Cardiovascular Disease Mortality. The Strong Heart Study. Circulation
109:733-739, 2004
72. Resnick HE. Foster GL. Prevalence of elevated ankle-brachial index in the United States 1999 to 2002. Am J Med 118:676-679, 2005
73. Salmenniemi U, Zacharova J, Ruotsalainen E et al. Association of adiponectin level and variants in the adiponectin gene with glucose metabolism, energy
expenditure and cytokines in offspring of type 2 diabetic patients. J Clin Endocrinol Metab 90:4216-4623, 2005.
74. Tsou PL, Jiang YD, Chang CC, Wei JN, Sung FC, Lin CC, Chiang CC, Tai TY, Chuang LM. Sex-Related Differences Between Adiponectin and Insulin Resistance in Schoolchildren. Diab Care 27: 308-313, 2004.
75. Wei JN, Chuang LM, Lin CC, Chiang CC, Lin RS, Sung FC. Childhood diabetes identified in mass urine screening program in Taiwan, 1993-1999. Diab Res Clin Pract 59: 201-206, 2003.
76. Soderberg S, Stegmayr B, Stenlund H, Sjostrom LG, Agren A, Johansson L, Weinehall L, Olsson T. Leptin, but not adiponectin, predicts stroke in males. J Intern Med. 256128-36, 2004.
77. Kumada M. Kihara S. Sumitsuji S. Kawamoto T. Matsumoto S. Ouchi N. Arita Y. Okamoto Y. Shimomura I. Hiraoka H. Nakamura T. Funahashi T. Matsuzawa Y. Osaka CAD Study Group. Coronary artery disease. Association of
hypoadiponectinemia with coronary artery disease in men. Arteriosclerosis, Thrombosis & Vascular Biology. 23:85-9, 2003.
78. Lacquemant C. Froguel P. Lobbens S. Izzo P. Dina C. Ruiz J. The adiponectin gene SNP+45 is associated with coronary artery disease in Type 2 (non-insulin-dependent) diabetes mellitus. Diabetic Medicine. 21:776-81, 2004.
79. Dzielinska Z. Januszewicz A. Wiecek A. Demkow M. Makowiecka-Ciesla M. Prejbisz A. Kadziela J. Mielniczuk R. Florczak E. Janas J. Januszewicz M. Ruzyllo W. Decreased plasma concentration of a novel anti-inflammatory
protein--adiponectin--in hypertensive men with coronary artery disease. Thrombosis Research. 110:365-9, 2003.
80. Ohashi K. Ouchi N. Kihara S. Funahashi T. Nakamura T. Sumitsuji S. Kawamoto T. Matsumoto S. Nagaretani H. Kumada M. Okamoto Y. Nishizawa H. Kishida K. Maeda N. Hiraoka H. Iwashima Y. Ishikawa K. Ohishi M. Katsuya T. Rakugi H.
Ogihara T. Matsuzawa Y. Adiponectin I164T mutation is associated with the metabolic syndrome and coronary artery disease. Journal of the American College of Cardiology. 43:1195-200, 2004.
81. Ouchi N. Kihara S. Funahashi T. Nakamura T. Nishida M. Kumada M. Okamoto Y. Ohashi K. Nagaretani H. Kishida K. Nishizawa H. Maeda N. Kobayashi H. Hiraoka H. Matsuzawa Y. Reciprocal association of C-reactive protein with
adiponectin in blood stream and adipose tissue. Circulation. 107:671-4, 2003.
82. Qi L, Li T, Rimm E, Zhang C, Rifai N, Hunter D, Doria A, Hu FB.The +276 polymorphism of the APM1 gene, plasma adiponectin concentration, and cardiovascular risk in diabetic men. Diabetes. 54:1607-10, 2005.
83. Krakoff J, Funahashi T, Stehouwer CDA, Schalkwijk CG,Tanaka S, Matsuzawa Y, Kobes S, Tataranni PA, Hanson RL, Knowler WC, Lindsay RS. Inflammatory markers, adiponectin, and risk of type 2 diabetes in the Pima India. Diabetes Care 26: 1745, 2003.
84. Snehalatha C, Mukesh B, Simon M, Viswanathan V, Haffner SM, Ramachandran A. Plasma Adiponectin Is an Independent Predictor of Type 2 Diabetes in Asian
Indian. Diabetes Care 26: 3226, 2003.
85. Model of complications of NIDDM. II. Analysis of the health benefits and cost-effectiveness of treating NIDDM with the goal of normoglycemia. Diabetes Care 20:725-734, 1997.
86. Adler AI, Stevens RJ, Manley SE, Bilous RW, Cull CA, Holman RR. Development and progression of nephropathy in type 2 diabetes: The United Kingdom Prospective Diabetes Study (UKPDS 64). Kidney International, 63:225–232, 2003.
87. Looker HC, Bennett PH, Krakoff J, Klein R, Knowler WC, Hanson RL. Longitudinal studies of incidence and progression of diabetic retinopathy assessed
by retinal photography in Pima Indians. Diab Care 26:320-326, 2003.
88. Perkins BA, Ficociello LH, Silva KH, Finkelstein DM, Warram JH, Krolewski AS. Regression of microalbuminuria in type 1 diabetes. NEJM 348: 2285-93, 2003
89. Nolting PR. de Groot E. Zwinderman AH. Buirma RJ. Trip MD. Kastelein JJ. Regression of carotid and femoral artery intima-media thickness in familial hypercholesterolemia: treatment with simvastatin. Arch Intern Med 163:1837-41,2003.
90. Matsuzaki M. Hiramori K. Imaizumi T. Kitabatake A. Hishida H. Nomura M. Fujii T. Sakuma I. Fukami K. Honda T. Ogawa H. Yamagishi M. Intravascular ultrasound evaluation of coronary plaque regression by low density lipoprotein-apheresis in familial hypercholesterolemia: the Low Density
Lipoprotein-Apheresis Coronary Morphology and Reserve Trial (LACMART). Journal of the American College of Cardiology. 40:220-7, 2002.